ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease

Image 2-Ongentys (opicapone)
Neurocrine Biosciences acquired rights from BIAL for the development and commercialisation of ONGENTYS in the US and Canada. Credit: Neurocrine Biosciences Inc.